SCHEMBL290981

SCHEMBL290981

CCCCOC(=O)NC(O)(Cc1ccccc1)C(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 3/20 0.50
TSHR P16473 2/20 0.50
L3MBTL1 Q9Y468 2/20 0.50
ALDH1A1 P00352 2/20 0.50
CYP3A4 P08684 1/20 0.50
MAPK1 P28482 1/20 0.50
POLB P06746 1/20 0.47
GAA P10253 1/20 0.46
CTSK P43235 3/20 0.44
SMN1; SMN2 Q16637 4/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2C19 P33261 1/20 0.44
RAB9A P51151 4/20 0.43
NPC1 O15118 3/20 0.43
LMNA P02545 2/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
RECQL P46063 2/20 0.43
GLS O94925 1/20 0.42
ITGB3 P05106 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Water SCHEMBL2946569 0.99 TDP1 (0.49) TDP1TSHRL3MBTL1ALDH1A1CYP3A4
SCHEMBL5699570 0.87 GAA (0.49) TDP1TSHRL3MBTL1ALDH1A1CYP3A4
SCHEMBL3658399 0.84 ITGB3 (0.53) TDP1TSHRL3MBTL1ALDH1A1CYP3A4
SCHEMBL4669846 0.79 EPHX1 (0.44) TSHRALDH1A1POLBHPGD
SCHEMBL5774552 0.78 EPHX1 (0.43) ALDH1A1POLBSMN1; SMN2CYP1A2CYP2C19
SCHEMBL6602876 0.78 POLB (0.41) TDP1TSHRL3MBTL1ALDH1A1CYP3A4
SCHEMBL3425341 0.77 CA12 (0.49) L3MBTL1ALDH1A1CYP3A4CTSKCYP2C19
SCHEMBL22059597 0.77 CA12 (0.49) L3MBTL1ALDH1A1CYP3A4CTSKCYP2C19
SCHEMBL5316226 0.77 ITGB3 (0.46) TDP1TSHRL3MBTL1ALDH1A1CYP3A4
Water SCHEMBL27509394 0.76 CTSS (0.48) ALDH1A1CYP3A4CTSKCYP2C19RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2454246-A2 SOLVATES OF DOCETAXEL Przedsiebiorstwo Produkcyjno-Wdrozeniowe (PL) 2012-05-23 EP claimed
WO-2010138010-A2 SOLVATES OF 4-ACETOXY-2α-BENZOYLOXY-5β,20-EPOXY-1,7β,10β-TRIHYDROXY-9-OXO-TAX-11 -EN- 13α-YL (2R,3S)-3-TERT-BUTOXYCARBONYLAMINO-2-HYDROXY-3-PHENYLPROPIONATE Przedsiębiorstwo Produkcyjno-Wdrożeniowe (PL) 2010-12-02 WO claimed
EP-2247582-A2 CRYSTALLINE FORMS OF DIMETHOXY DOCETAXEL AND METHODS FOR PREPARING SAME Aventis Pharma S.A. (FR) 2010-11-10 EP claimed
WO-2009115655-A2 CRYSTALLINE FORMS OF DIMETHOXY DOCETAXEL AND METHODS FOR PREPARING SAME AVENTIS PHARMA S.A. (FR) 2009-09-24 WO claimed
EP-1667986-A1 DIMETHOXY DOCETAXEL ACETONE SOLVATE ET METHOD FOR THE PREPARATION THEREOF Aventis Pharma S.A. (FR) 2006-06-14 EP claimed
WO-2005028462-A1 DIMETHOXY DOCETAXEL ACETONE SOLVATE ET METHOD FOR THE PREPARATION THEREOF AVENTIS PHARMA S.A. (FR) 2005-03-31 WO claimed
EP-1176957-A1 METHOD FOR TREATING ABNORMAL CELL PROLIFERATION IN THE BRAIN Aventis Pharma S.A. (FR) 2002-02-06 EP claimed
WO-2000066113-A1 METHOD FOR TREATING ABNORMAL CELL PROLIFERATION IN THE BRAIN AVENTIS PHARMA S.A. (FR) 2000-11-09 WO claimed
EP-0876361-A1 4,10$g(b)-DIACETOXY-2$g(a)-BENZOYLOXY-5$g(b),20-EPOXY-1-HYDROXY-9-OXO-19-NOR-CYCLOPROPA G]TAX-11-ENE-13$g(a)-YL (2R,3S)-TERT-BUTOXYCARBONYLAMINO-2-HYDROXY-3-PHENYLPROPIONATE DIHYDRATE, AND METHOD FOR PREPARING SAME Aventis Pharma S.A. (FR) 1998-11-11 EP claimed
WO-1997021695-A1 4,10β-DIACETOXY-2α-BENZOYLOXY-5β,20-EPOXY-1-HYDROXY-9-OXO-19-NOR-CYCLOPROPA[G]TAX-11-ENE-13α-YL (2R,3S)-TERT-BUTOXYCARBONYLAMINO-2-HYDROXY-3-PHENYLPROPIONATE DIHYDRATE, AND METHOD FOR PREPARING SAME RHONE-POULENC RORER S.A. (FR) 1997-06-19 WO claimed
EP-3258931-A1 USE OF CABAZITAXEL IN THE TREATMENT OF PROSTATE CANCER Erasmus University Medical Center Rotterdam (NL) 2017-12-27 EP disclosed
WO-2016133387-A1 USE OF CABAZITAXEL IN THE TREATMENT OF PROSTATE CANCER ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM (NL) 2016-08-25 WO disclosed
WO-2015104417-A1 USE OF CABAZITAXEL FOR THE TREATMENT OF GASTRIC ADENOCARCINOMA AVENTIS PHARMA S.A. (FR) 2015-07-16 WO disclosed
WO-2015036507-A1 USE OF CABAZITAXEL IN PATIENTS WITH METASTATIC NSCLC PROGRESSING AFTER DOCETAXEL-BASED TREATMENT AVENTIS PHARMA S.A. (FR) 2015-03-19 WO disclosed
EP-2493466-A1 NOVEL ANTITUMORAL USE OF CABAZITAXEL Aventis Pharma S.A. (FR) 2012-09-05 EP disclosed
WO-2000066113-A1 METHOD FOR TREATING ABNORMAL CELL PROLIFERATION IN THE BRAIN AVENTIS PHARMA S.A. (FR) 2000-11-09 WO disclosed
EP-0876361-A1 4,10$g(b)-DIACETOXY-2$g(a)-BENZOYLOXY-5$g(b),20-EPOXY-1-HYDROXY-9-OXO-19-NOR-CYCLOPROPA G]TAX-11-ENE-13$g(a)-YL (2R,3S)-TERT-BUTOXYCARBONYLAMINO-2-HYDROXY-3-PHENYLPROPIONATE DIHYDRATE, AND METHOD FOR PREPARING SAME Aventis Pharma S.A. (FR) 1998-11-11 EP disclosed
WO-1997021695-A1 4,10β-DIACETOXY-2α-BENZOYLOXY-5β,20-EPOXY-1-HYDROXY-9-OXO-19-NOR-CYCLOPROPA[G]TAX-11-ENE-13α-YL (2R,3S)-TERT-BUTOXYCARBONYLAMINO-2-HYDROXY-3-PHENYLPROPIONATE DIHYDRATE, AND METHOD FOR PREPARING SAME RHONE-POULENC RORER S.A. (FR) 1997-06-19 WO disclosed
EP-0770070-A1 METHOD FOR PREPARING 4-ACETOXY-2ALPHA-BENZOYLOXY-5ALPHA,20-EPOXY-1,7BETA,10BETA-TRIHYDROXY-9-OXO-TAX-11-EN-13ALPHA-YL(2R,3S)-3-TERT-BUTOXYCARBONYLAMINO-2-HYDROXY-3-PHENYLPROPIONATE TRIHYDRATE Aventis Pharma S.A. (FR) 1997-05-02 EP disclosed
WO-1996001815-A1 METHOD FOR PREPARING 4-ACETOXY-2α-BENZOYLOXY-5β,20-EPOXY-1,7β,10β-TRIHYDROXY-9-OXO-TAX-11-EN-13α-YL(2R,3S)-3-TERT-BUTOXYCARBONYLAMINO-2-HYDROXY-3-PHENYLPROPIONATE TRIHYDRATE RHONE-POULENC RORER S.A. (FR) 1996-01-25 WO disclosed